collection
https://read.qxmd.com/read/35288443/lipoprotein-a-a-risk-factor-for-atherosclerosis-and-an-emerging-therapeutic-target
#1
REVIEW
Stefania Angela Di Fusco, Marcello Arca, Pietro Scicchitano, Alessandro Alonzo, Francesco Perone, Michele Massimo Gulizia, Domenico Gabrielli, Fabrizio Oliva, Giuseppe Imperoli, Furio Colivicchi
Lipoprotein(a) (Lp(a)) is a complex circulating lipoprotein, and increasing evidence has demonstrated its role as a risk factor for atherosclerotic cardiovascular disease (ASCVD) and as a possible therapeutic target. Lp(a) atherogenic effects are attributed to several potential mechanisms in addition to cholesterol accumulation in the arterial wall, including proinflammatory effects mainly mediated by oxidised phospholipids. Several studies have found a causal and independent relationship between Lp(a) levels and cardiovascular risk...
December 13, 2022: Heart
https://read.qxmd.com/read/34969397/myocardial-involvement-in-children-with-post-covid-multisystem-inflammatory-syndrome-a-cardiovascular-magnetic-resonance-based-multicenter-international-study-the-cardovid-registry
#2
MULTICENTER STUDY
Florence A Aeschlimann, Nilanjana Misra, Tarique Hussein, Elena Panaioli, Jonathan H Soslow, Kimberly Crum, Jeremy M Steele, Steffen Huber, Simona Marcora, Paolo Brambilla, Supriya Jain, Maria Navallas, Valentina Giuli, Beate Rücker, Felix Angst, Mehul D Patel, Arshid Azarine, Pablo Caro-Domínguez, Annachiara Cavaliere, Giovanni Di Salvo, Francesca Ferroni, Gabriella Agnoletti, Laurent Bonnemains, Duarte Martins, Nathalie Boddaert, James Wong, Kuberan Pushparajah, Francesca Raimondi
BACKGROUND: Recent evidence shows an association between coronavirus disease 2019 (COVID-19) infection and a severe inflammatory syndrome in children. Cardiovascular magnetic resonance (CMR) data about myocardial injury in children are limited to small cohorts. The aim of this multicenter, international registry is to describe clinical and cardiac characteristics of multisystem inflammatory syndrome in children (MIS-C) associated with COVID-19 using CMR so as to better understand the real extent of myocardial damage in this vulnerable cohort...
December 30, 2021: Journal of Cardiovascular Magnetic Resonance
https://read.qxmd.com/read/34396236/cardiac-tumors-jacc-cardiooncology-state-of-the-art-review
#3
REVIEW
Sara Tyebally, Daniel Chen, Sanjeev Bhattacharyya, Abdallah Mughrabi, Zeeshan Hussain, Charlotte Manisty, Mark Westwood, Arjun K Ghosh, Avirup Guha
Cardiac masses are rare, but remain an important component of cardio-oncology practice. These include benign tumors, malignant tumors (primary and secondary) and tumor-like conditions (e.g., thrombus, Lambl's excrescences, and pericardial cyst). The advent of multimodality imaging has enabled identification of the etiology of cardiac masses in many cases, especially in conjunction with information from clinical settings. This paper provides a comprehensive review of the epidemiology, clinical presentation, imaging, diagnosis, management, and outcomes of cardiac masses...
June 2020: JACC CardioOncology
https://read.qxmd.com/read/34422918/tavr-in-cancer-patients-comprehensive-review-meta-analysis-and-meta-regression
#4
Konstantinos Marmagkiolis, Dominique J Monlezun, Mehmet Cilingiroglu, Cindy Grines, Joerg Herrmann, Konstantinos Pavlos Toutouzas, Ismail Ates, Cezar Iliescu
Objectives: This study sought to systematically analyze the available clinical evidence on TAVR therapy in cancer patients with symptomatic severe AS. Background: Aortic stenosis is the most common valvular heart disease in the world. TAVR has expanded the treatment options for this lethal disease process. The safety and efficacy of TAVR in cancer patients has not yet been reliably established. We thus conducted the largest known multi-center meta-analysis on TAVR and cancer status. Methods: We performed a literature search using PubMed, EMBASE, and Cochrane Central Register of Controlled Trials from January 2015 to 2020...
2021: Frontiers in Cardiovascular Medicine
https://read.qxmd.com/read/34423240/acute-cardiac-manifestations-under-immune-checkpoint-inhibitors-beware-of-the-obvious-a-case-report
#5
Dimitri Arangalage, Anna Giulia Pavon, Berna C Özdemir, Olivier Michielin, Jurg Schwitter, Pierre Monney
Background: Immune checkpoint inhibitors (ICI) have revolutionized the management of many cancer types by drastically improving the median survival rate of patients. However, this efficiency comes at the cost of a high rate of immune-related adverse events, including lethal cardiac manifestations. Rapidly fatal cases of ICI-induced myocarditis have been reported and drawn considerable attention over the past years. However, it is essential to bear in mind that not all cardiac events occurring under ICI therapy are necessarily myocarditis...
August 2021: European Heart Journal. Case Reports
https://read.qxmd.com/read/34456641/anmco-position-paper-cardio-oncology-in-the-covid-era-co-and-co
#6
JOURNAL ARTICLE
Irma Bisceglia, Domenico Gabrielli, Maria Laura Canale, Giuseppina Gallucci, Iris Parrini, Fabio Maria Turazza, Giulia Russo, Nicola Maurea, Vincenzo Quagliariello, Chiara Lestuzzi, Stefano Oliva, Stefania Angela Di Fusco, Fabiana Lucà, Luigi Tarantini, Paolo Trambaiolo, Michele Massimo Gulizia, Furio Colivicchi
The COVID-19 pandemic and its impact on patients with cancer and cardiovascular disease have confirmed the particular vulnerability of these populations. Indeed, not only a higher risk of contracting the infection has been reported but also an increased occurrence of a more severe course and unfavourable outcome. Beyond the direct consequences of COVID-19 infection, the pandemic has an enormous impact on global health systems. Screening programmes and non-urgent tests have been postponed; clinical trials have suffered a setback...
August 2021: European Heart Journal Supplements: Journal of the European Society of Cardiology
https://read.qxmd.com/read/34514707/trends-in-cardiovascular-mortality-of-cancer-patients-in-the-us-over-two-decades-1999-2019
#7
JOURNAL ARTICLE
Ofer Kobo, Sophia Khattak, Juan Lopez-Mattei, Harriette G C Van Spall, Michelle Graham, Richard K Cheng, Mohammed Osman, Louise Sun, Waqas Ullah, David L Fischman, Ariel Roguin, Mohamed O Mohamed, Mamas A Mamas
BACKGROUND: Cancer is the second most common cause of death globally after cardiovascular disease, and cancer patients are at an increased risk of CV death. This recognition has led to publication of cardio-oncological guidelines and to the widespread adoption of dedicated cardio-oncology services in many institutes. However, it is unclear whether there has been a change in the incidence of CV death in cancer patients. METHODS AND RESULTS: Using Centers for Disease Control and Prevention Wide-Ranging, Online Data for Epidemiologic Research (CDC WONDER) Multiple Cause of Death dataset, we determined national trends in age-standardised mortality rates attributed to cardiovascular diseases in patients with and without cancer, from 1999 to 2019, stratified by cancer type, age, gender, race, and place of residence (state and urbanisation status)...
November 2021: International Journal of Clinical Practice
https://read.qxmd.com/read/34454967/cardiovascular-magnetic-resonance-characterisation-of-anthracycline-cardiotoxicity-in-adults-with-normal-left-ventricular-ejection-fraction
#8
JOURNAL ARTICLE
Iwan Harries, Bostjan Berlot, Natasha Ffrench-Constant, Matthew Williams, Kate Liang, Estefania De Garate, Anna Baritussio, Giovanni Biglino, Juan Carlos Plana, Chiara Bucciarelli-Ducci
BACKGROUND: Anthracycline therapy may lead to changes in cardiac structure and function not detectable by solely evaluating left ventricular ejection fraction (LVEF). OBJECTIVES: We hypothesized that cardiovascular magnetic resonance (CMR) would identify structural and functional myocardial abnormalities in anthracycline-treated cancer survivors with normal LVEF, compared to a matched control population. METHODS: Forty-five cancer survivors (56 ± 16 yrs...
November 15, 2021: International Journal of Cardiology
https://read.qxmd.com/read/34461622/cardio-oncology-rehabilitation-core-exercise-prescription-and-programming-a-practical-guide
#9
JOURNAL ARTICLE
Adam M Shultz, Ray W Squires, John Y Shin, Urshila Durani, Priyanka A Pophali
BACKGROUND: Patients with cancer almost universally report diminished health-related quality of life. Many patients experience persistent fatigue and most have below-average exercise capacities. Despite the publication of exercise guidelines for cancer survivors that encourage physical activity, few patients exercise on a regular basis. Cardiovascular disease is a major cause of death in early-stage malignancies. Exercise training has been demonstrated to decrease cardiovascular events in patients with cancer...
September 1, 2021: Journal of Cardiopulmonary Rehabilitation and Prevention
https://read.qxmd.com/read/34466757/cardio-oncology-understanding-the-intersections-between-cardiac-metabolism-and-cancer-biology
#10
REVIEW
Anja Karlstaedt, Matthew Barrett, Ray Hu, Seth Thomas Gammons, Bonnie Ky
An important priority in the cardiovascular care of oncology patients is to reduce morbidity and mortality, and improve the quality of life in cancer survivors through cross-disciplinary efforts. The rate of survival in cancer patients has improved dramatically over the past decades. Nonetheless, survivors may be more likely to die from cardiovascular disease in the long term, secondary, not only to the potential toxicity of cancer therapeutics, but also to the biology of cancer. In this context, efforts from basic and translational studies are crucial to understanding the molecular mechanisms causal to cardiovascular disease in cancer patients and survivors, and identifying new therapeutic targets that may prevent and treat both diseases...
August 2021: JACC. Basic to Translational Science
https://read.qxmd.com/read/26289314/glycosylation-in-cancer-mechanisms-and-clinical-implications
#11
REVIEW
Salomé S Pinho, Celso A Reis
Despite recent progress in understanding the cancer genome, there is still a relative delay in understanding the full aspects of the glycome and glycoproteome of cancer. Glycobiology has been instrumental in relevant discoveries in various biological and medical fields, and has contributed to the deciphering of several human diseases. Glycans are involved in fundamental molecular and cell biology processes occurring in cancer, such as cell signalling and communication, tumour cell dissociation and invasion, cell-matrix interactions, tumour angiogenesis, immune modulation and metastasis formation...
September 2015: Nature Reviews. Cancer
https://read.qxmd.com/read/34183072/tavr-and-cancer-machine-learning-augmented-propensity-score-mortality-and-cost-analysis-in-over-30-million-patients
#12
JOURNAL ARTICLE
Dominique J Monlezun, Logan Hostetter, Prakash Balan, Nicolas Palaskas, Juan Lopez-Mattei, Mehmet Cilingiroglu, Zaza Iakobishvili, Michael Ewer, Konstantinos Marmagkiolis, Cezar Iliescu
INTRODUCTION: Cardiovascular disease (CVD) and cancer are the top mortality causes globally, yet little is known about how the diagnosis of cancer affects treatment options in patients with hemodynamically compromising aortic stenosis (AS). Patients with cancer often are excluded from aortic valve replacement (AVR) trials including trials with transcatheter AVR (TAVR) and surgical AVR (SAVR). This study looks at how cancer may influence treatment options and assesses the outcome of patients with cancer who undergo SAVR or TAVR intervention...
June 28, 2021: Cardio-Oncology
https://read.qxmd.com/read/34268341/cardiac-magnetic-resonance-predicting-outcomes-among-patients-at-risk-for-cardiac-al-amyloidosis
#13
JOURNAL ARTICLE
Ali M Agha, Nicolas Palaskas, Amit R Patel, Jeanne DeCara, Purvi Parwani, Cezar Iliescu, Jean B Durand, Peter Kim, Saamir Hassan, Gregory Gladish, Hans C Lee, Gregory P Kaufman, Juan C Lopez-Mattei
Introduction: Patients with systemic AL amyloidosis (AL) should be evaluated for cardiac amyloidosis (CA), as prognosis is strongly related to cardiac involvement. We assessed the characteristics of patients referred to cardiac magnetic resonance (CMR) with suspected CA from a cancer center and determine predictors of mortality/heart failure hospitalizations (HFH). Methods: Forty-four consecutive patients referred for CMR with suspected CA were retrospectively included. Variables collected included cardiac biomarkers, in addition to echocardiographic and CMR variables...
2021: Frontiers in Cardiovascular Medicine
https://read.qxmd.com/read/34154667/a-new-classification-of-cardio-oncology-syndromes
#14
REVIEW
Rudolf A de Boer, Joseph Pierre Aboumsallem, Valentina Bracun, Douglas Leedy, Richard Cheng, Sahishnu Patel, David Rayan, Svetlana Zaharova, Jennifer Rymer, Jennifer M Kwan, Joshua Levenson, Claudio Ronco, Paaladinesh Thavendiranathan, Sherry-Ann Brown
Increasing evidence suggests a multifaceted relationship exists between cancer and cardiovascular disease (CVD). Here, we introduce a 5-tier classification system to categorize cardio-oncology syndromes (COS) that represent the aspects of the relationship between cancer and CVD. COS Type I is characterized by mechanisms whereby the abrupt onset or progression of cancer can lead to cardiovascular dysfunction. COS Type II includes the mechanisms by which cancer therapies can result in acute or chronic CVD. COS Type III is characterized by the pro-oncogenic environment created by the release of cardiokines and high oxidative stress in patients with cardiovascular dysfunction...
June 21, 2021: Cardio-Oncology
https://read.qxmd.com/read/34194987/high-grade-heart-block-associated-with-ibrutinib-therapy
#15
Alexander R Vartanov, Benjamin L Lampson, Eric D Jacobsen, Edwin P Alyea, Javid J Moslehi, Jennifer R Brown
No abstract text is available yet for this article.
June 2021: HeartRhythm Case Reports
https://read.qxmd.com/read/34270717/frailty-in-cardiology-definition-assessment-and-clinical-implications-for-general-cardiology-a-consensus-document-of-the-council-for-cardiology-practice-ccp-association-for-acute-cardio-vascular-care-acvc-association-of-cardiovascular-nursing-and-allied-professions
#16
JOURNAL ARTICLE
Dimitri Richter, Luigina Guasti, David Walker, Ekaterini Lambrinou, Christos Lionis, Ana Abreu, Irina Savelieva, Stefano Fumagalli, Mario Bo, Bianca Rocca, Magnus T Jensen, Luc Pierard, Isabella Sudano, Victor Aboyans, Riccardo Asteggiano
Frailty is a health condition leading to many adverse clinical outcomes. The relationship between frailty and advanced age, multimorbidity and disability has a significant impact on healthcare systems. Frailty increases cardiovascular (CV) morbidity and mortality both in patients with or without known CV disease. Though the recognition of this additional risk factor has become increasingly clinically relevant in CV diseases, uncertainty remains about operative definitions, screening, assessment, and management of frailty...
February 19, 2022: European Journal of Preventive Cardiology
https://read.qxmd.com/read/34076246/interactions-between-cardiology-and-oncology-drugs-in-precision-cardio-oncology
#17
REVIEW
Sailaja Kamaraju, Meera Mohan, Svetlana Zaharova, Brianna Wallace, Joseph McGraw, James Lokken, John Tierney, Elizabeth Weil, Olubadewa Fatunde, Sherry-Ann Brown
Recent advances in treatment have transformed the management of cancer. Despite these advances, cardiovascular disease remains a leading cause of death in cancer survivors. Cardio-oncology has recently evolved as a subspecialty to prevent, diagnose, and manage cardiovascular side effects of antineoplastic therapy. An emphasis on optimal management of comorbidities and close attention to drug interactions are important in cardio-oncologic care. With interdisciplinary collaboration among oncologists, cardiologists, and pharmacists, there is potential to prevent and reduce drug-related toxicities of treatments...
June 11, 2021: Clinical Science (1979-)
https://read.qxmd.com/read/33190775/toxicities-associated-with-immunotherapy-and-approach-to-cardiotoxicity-with-novel-cancer-therapies
#18
REVIEW
Cristina Gutierrez, Prabalini Rajendram, Stephen M Pastores
In recent years, major advances in oncology especially the advent of targeted agents and immunotherapies (immune checkpoint inhibitors [ICIs] and chimeric antigen receptor [CAR] T-cell therapy) have led to improved quality of life and survival rates in patients with cancer. This article focuses on the clinical features, and grading and management of toxicities associated with ICIs and CAR T-cell therapy. In addition, because cardiotoxicity is one of the most harmful effects of anticancer therapeutics, we describe the risk factors and mechanisms of cardiovascular injury associated with newer agents, screening technologies for at-risk patients, and preventive and treatment strategies...
January 2021: Critical Care Clinics
https://read.qxmd.com/read/31983487/rehabilitation-needs-in-cancer-treatment-related-cardiotoxicity
#19
JOURNAL ARTICLE
Edith Pituskin, Amy A Kirkham, Nanette Cox-Kennett, Rebecca Dimitry, John Dimitry, Ian Paterson, Gabor T Gyenes
OBJECTIVES: To examine and summarize current international guidelines regarding cardiovascular risk reduction before and during cancer therapy, and to discuss the emerging role of cardio-oncology as a subspecialty in cancer care and the role of cardio-oncology rehabilitation. DATA SOURCES: Published articles and guidelines. CONCLUSION: With improvements in cancer detection and the use of novel adjuvant therapies, an increasing number of individuals now survive a cancer diagnosis...
February 2020: Seminars in Oncology Nursing
https://read.qxmd.com/read/31980441/pericardial-diseases-in-patients-with-cancer-contemporary-prevalence-management-and-outcomes
#20
REVIEW
Massimo Imazio, Marzia Colopi, Gaetano Maria De Ferrari
Neoplastic pericardial effusion is a common and serious manifestation of advanced malignancies. Lung and breast carcinoma, haematological malignancies, and gastrointestinal cancer are the most common types of cancer involving the pericardium. Pericardial involvement in neoplasia may arise from several different pathophysiological mechanisms and may be manifested by pericardial effusion with or without tamponade, effusive-constrictive pericarditis and constrictive pericarditis. Management of these patients is a complex multidisciplinary problem, affected by clinical status and prognosis of patients...
April 2020: Heart
label_collection
label_collection
4812
1
2
2020-01-30 01:23:56
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.